Revolution Medicines is soaring after a 130% stock surge this year, fueled by billionaire Stanley Druckenmiller’s massive bet that’s already more than doubled in value. The biotech firm is pioneering targeted cancer therapies to replace chemo, with its lead drug Daraxonrasib showing patients with pancreatic cancer living twice as long—earning FDA fast-track status and paving the way for global approval. Backed by major investors like BlackRock and Vanguard, Revolution’s breakthrough platform targets previously untreatable RAS proteins, offering hope for lung, colorectal, and pancreatic cancers. With multiple late-stage candidates in the pipeline and a strong cash reserve, the company’s high-risk, high-reward play is capturing investor imagination in the biotech world.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
